ARCH Venture Partners has promoted Kristina Burow and Paul Thurk to the position of partner. Burow joined the firm’s San Francisco office in 2002, and is a co-founder and director of Sapphire Energy. Thurk joined the firm’s Austin, Texas office in 2000, and co-founded Innovalight.
ARCH Venture Partners announced the promotion of former Principals Kristina Burow and Paul Thurk to Partners of the firm.
Kristina Burow joined ARCH in 2002 and works out of ARCH’s San Francisco, CA office. Burow is a co-founder and director of Sapphire Energy and has participated in the development of several ARCH portfolio companies including Ensemble Discovery, Lycera, Achaogen, Kythera Biopharmaceuticals, Ikaria, and Quanterix. ARCH Co-founder and Managing Director Robert Nelsen commented, “Kristina has already helped to create some great companies at ARCH, such as Sapphire Energy, and we look forward to creating many more game-changing companies together.”
Burow’s investment focus includes biotechnology, alternative energy and chemicals. Burow joined ARCH from the Novartis BioVenture Fund, and was an early employee at the Genomics Institute of the Novartis Research Foundation (GNF). She was a co-inventor of key technology platforms that formed the core of Kalypsys, a GNF spin-off company.
Paul Thurk began his tenure with ARCH in 2000 as a Kauffman Fellow in the Austin, TX office. He co-founded Innovalight, a solar cell developer, and served as its initial CEO. He recently co-founded a new company ARCH is incubating in the clean energy sector. Thurk also has participated in the development of ARCH portfolio companies Nitronex, Cambrios and Semprius, and has been a key part of ARCH’s efforts at Sandia National Laboratories in their Entrepreneur-In-Residence Program with the U.S. Department of Energy. Clint Bybee, a Co-founder and Managing Director of ARCH said, “Paul has been a key catalyst in creating leading companies in important emerging markets and we are excited to recognize his hard work and solid contributions.”
Thurk focuses on investments in the physical sciences including semiconductors, nanotechnology, optics, and advanced materials with special interest in sold-state lighting. Prior to ARCH, Thurk was with the investment firm SSM Ventures and also with NABS, a supplier of electronics components, where he established subsidiary operations across five countries and launched supply chain management programs.
About ARCH Venture Partners
ARCH Venture Partners focuses on creating early-stage technology companies in the life, physical and information sciences, which emanate from universities, national laboratories and corporate research labs. With $1.5 billion under management, ARCH has invested in the earliest rounds of more than 135 companies over a 22-year history. Early-stage biotechnology investments include Illumina, Ikaria, Alnylam Pharmaceuticals, Aviron (acquired by MedImmune), XenoPort, Caliper Life Sciences, Adolor, Array BioPharma, deCode Genetics, GenVec, NeurogesX, R2 Technology (acquired by Hologic), Kythera Biopharmaceuticals and Trubion Pharmaceuticals, among others. ARCH was also a seed investor in companies such as New Era of Networks (acquired by Sybase), Sapphire Energy, Nanosys, Impinj, Innovalight, Xtera Communications and MicroOptical Devices (acquired by Emcore).
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.